Dabigatran Etexilate and Famotidine Injection
Determining the interaction of Dabigatran Etexilate and Famotidine Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using dabigatran if you are receiving famotidine for a gastrointestinal condition such as stomach ulcer or bleeding. Treatment with dabigatran may worsen your symptoms and increase the risk of bleeding. Contact your doctor if you experience potential signs and symptoms of bleeding such as dizziness; lightheadedness; red or black stools; coughing up or vomiting blood or blood clots; and abdominal pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Patients with gastrointestinal conditions may have an increased risk of gastrointestinal bleeding during concomitant treatment with dabigatran etexilate and proton pump inhibitors or H2 blockers. In addition, pantoprazole resulted in an approximately 30% decrease in dabigatran systemic exposure (AUC). Diminished clinical effect may occur, although no dosage adjustment is recommended for dabigatran etexilate. The pharmacokinetics of pantoprazole were not significantly altered by dabigatran. Pantoprazole and other proton pump inhibitors were also coadministered with dabigatran in clinical trials for the prevention of venous thromboembolic events after hip- or knee-replacement surgery, and no effects on bleeding or efficacy were observed. Ranitidine had no significant effects on the absorption of dabigatran.
MANAGEMENT: Patients should be monitored for signs of gastrointestinal bleeding and advised to promptly report any symptoms to their physician, such as abdominal pain, dizziness, lightheadedness, vomiting blood, anorexia, and/or black, tarry stools.
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Pradax (dabigatran)." Boehringer Ingelheim (Canada) Ltd, Burlington, IA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim, Ridgefield, CT.
Generic Name: dabigatran
Brand name: Pradaxa
Synonyms: Dabigatran
Generic Name: famotidine
Brand name: Pepcid, Heartburn Relief, Pepcid AC, Pepcid AC Maximum Strength, Pepcid AC Chewable Tablets, Pepcid Oral Suspension
Synonyms: Famotidine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dabigatran Etexilate-Famotidine Injection Solution
- Dabigatran Etexilate-Famotidine Oral Suspension
- Dabigatran Etexilate-Famotidine Tablets
- Dabigatran Etexilate-Famotidine, Calcium Carbonate, and Magnesium Hydroxide
- Dabigatran Etexilate-Famvir
- Dabigatran Etexilate-Fanapt
- Famotidine Injection-Dabigatran Etexilate Mesylate
- Famotidine Injection-Dabrafenib
- Famotidine Injection-Dabrafenib Mesylate
- Famotidine Injection-Dacarbazine
- Famotidine Injection-Dacarbazine Intravenous, Injection
- Famotidine Injection-Daclatasvir